Sobi and Hellenic Institute Report Results of Anakinra in P-III SAVE-MORE Study for Hospitalized Patients with COVID-19 Pneumonia

May 3, 2021 Auto Bot Clinical Trials, P-III, pneumonia, Sobi 0

Shots:

  • The P-III SAVE-MORE study involves assessing the efficacy and safety of anakinra (100mg/day, SC for up to 10 days) + SoC guided by suPAR vs PB0 + SOC in 600 hospitalized patients in mod. to sev. COVID-19 pneumonia over 28days across 40 sites in Greece and Italy
  • The study demonstrated improvement in the overall clinical outcomes by 64% @28 days as measured by the ordinal scale of the 11-point CPS, reduction in either death or progression to severe respiratory failure and increase the no. of patients who were discharged from hospital with no evidence of COVID-19 infection
  • Sobi plans to discuss the results with regulatory authorities to evaluate the possibility of approval

Click here to­ read full press release/ article | Ref: Sobi | Image: Sobi

The post Sobi and Hellenic Institute Report Results of Anakinra in P-III SAVE-MORE Study for Hospitalized Patients with COVID-19 Pneumonia first appeared on PharmaShots.